The Economics of Drug Discovery and the Ultimate Valuation of Pharmacotherapies in the Marketplace | Zendy

Sollano JA | Zendy; Kirsch JM | Zendy; Bala MV | Zendy; Chambers MG | Zendy; Harpole LH | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

The Economics of Drug Discovery and the Ultimate Valuation of Pharmacotherapies in the Marketplace

Author(s) -

Sollano JA,

Kirsch JM,

Bala MV,

Chambers MG,

Harpole LH

Publication year - 2008

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2008.117

Subject(s) - clinical pharmacology , valuation (finance) , reimbursement , business , drug discovery , health economics , drug development , actuarial science , drug , pharmacology , economics , medicine , health care , finance , bioinformatics , economic growth , biology

Although it is commonly believed that the innovation of new medicines is of paramount importance for improving the health and quality of life of patients, there is also a keen recognition regarding upward‐spiraling costs of innovation, drug discovery, and drug development against a backdrop of dwindling successes in research and development (R&D) efforts. We propose a new model of valuation of pharmacotherapies that attempts to secure an adequate return on investment in innovation by ensuring optimal pricing and reimbursement. Clinical Pharmacology & Therapeutics (2008); 84 , 2, 263–266 doi: 10.1038/clpt.2008.117

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research